Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Mirum Pharmaceuticals Inc (NQ: MIRM )

24.03 +0.15 (+0.63%)
Streaming Delayed Price Updated: 12:20 PM EST, Feb 2, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 84,711
Open 24.02
Bid (Size) 23.97 (2)
Ask (Size) 24.07 (2)
Prev. Close 23.88
Today's Range 23.69 - 24.27
52wk Range 17.32 - 30.55
Shares Outstanding 36,870,380
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Mirum Pharmaceuticals, Inc.
Via Business Wire
AT&T To Rally Over 15%? Here Are 10 Other Analyst Forecasts For Tuesday
Keybanc boosted Five Below, Inc. (NASDAQ: FIVE) price target from $188 to $200. Keybanc analyst Bradley Thomas maintained an Overweight rating on the stock. Five Below shares fell 1.6% to $183.92 in... 
Via Benzinga

Performance

YTD
+24.64%
+24.64%
1 Month
+24.64%
+24.64%
3 Month
+3.40%
+3.40%
6 Month
+3.13%
+3.13%
1 Year
+26.81%
+26.81%

More News

Read More
Mirum Pharmaceuticals Announces Preliminary Unaudited LIVMARLI 2022 Net Revenue and Provides Corporate Updates
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Mirum Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Mirum Pharmaceuticals's Return On Capital Employed Insights
Via Benzinga
Europe Approves Mirum Pharma's Drug For Rare Genetic Liver Disease
Via Benzinga
Mirum Pharmaceuticals Appoints Lon Cardon to Board of Directors
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Mirum Pharmaceuticals’ LIVMARLI (maralixibat) Approved by the European Commission for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome Two Months and Older
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Where Mirum Pharmaceuticals Stands With Analysts
Via Benzinga
Mirum Pharmaceuticals Provides Development Program Updates
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Robinhood, MicroStrategy And Other Big Losers From Wednesday
Via Benzinga
Why Merrimack Pharmaceuticals Shares Jumped Around 213%; Here Are 114 Biggest Movers From Yesterday
Via Benzinga
Why RumbleON Shares Are Trading Higher By Around 28%? Here Are 84 Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Mirum Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Mirum Presents New Data from LIVMARLI Phase 3 PFIC Study and ALGS Infant Study in Late-Breaker Presentations at The Liver Meeting of AASLD
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Mirum Pharmaceuticals to Announce Third Quarter 2022 Financial Results and Host Conference Call on November 9, 2022
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Mirum’s LIVMARLI Data Featured in Two Late-Breaker Presentations at The Liver Meeting of the American Association for the Study of Liver Diseases
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Why Taysha Gene Therapies Shares Jumped Over 97%; Here Are 70 Biggest Movers From Yesterday
Via Benzinga
Analysts Expect Mirum Pharma's Liver Disease Candidate Might Exceed Rival Product's Penetration
Via Benzinga
Positive Topline Data Announced from Mirum’s LIVMARLI Phase 3 MARCH Study in Progressive Familial Intrahepatic Cholestasis (PFIC)
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Mirum Pharmaceuticals’ LIVMARLI Data Highlighting Quality of Life and Sleep Improvements in Patients with Alagille Syndrome Published in Journal of Pediatrics
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Mirum Pharmaceuticals Announces Positive CHMP Opinion for LIVMARLI® (maralixibat) Oral Solution for Cholestatic Pruritus in Patients with Alagille Syndrome Two Months of Age and Older
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Mirum Pharmaceuticals Presents Long-Term LIVMARLI® (maralixibat) Data and New Alagille Syndrome Caregiver Burden Analysis at NASPGHAN 2022 Annual Meeting
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.